Stockscreener 앱 받기
1.01
4.12%
0.04
시간 외 거래:
1.01
전일 마감가:
$0.97
열려 있는:
$1.01
하루 거래량:
117
Relative Volume:
0.12
시가총액:
$N/A
수익:
$601.00K
순이익/손실:
$-18.63M
주가수익비율:
-0.0998
EPS:
-10.1227
순현금흐름:
$-16.21M
1주 성능:
+4.12%
1개월 성능:
+1.00%
6개월 성능:
+1.00%
1년 성능:
+48.53%
1일 변동 폭
$1.01
$1.01
1주일 범위
$1.01
$1.01
52주 변동 폭
$0.50
$1.50
Vaccinex Inc Stock (VCNX) Company Profile
Compare VCNX vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VCNX
Vaccinex Inc
|
1.01 | 0 | 601.00K | -18.63M | -16.21M | -10.12 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vaccinex Inc Stock (VCNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-09-23 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2018-09-04 | 개시 | Ladenburg Thalmann | Buy |
Vaccinex Inc 주식(VCNX)의 최신 뉴스
Vaccinex stock trades flat at USD 1.00 after a thin session - AD HOC NEWS
Vaccinex stock holds at 1.00 dollars as investors await fresh trial and earnings updates - AD HOC NEWS
Vaccinex Stock Price Forecast. Should You Buy VCNX? - StockInvest.us
VCNX stock needs fresh market context - ad-hoc-news.de
BCAB Stock Price and Chart — OTC:BCAB - TradingView
Vaccinex Inc. (VCNX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
MSN Money - MSN
School Vaccine Mandates - Encyclopedia Britannica
CHGA Stock Price and Chart — NASDAQ:CHGA - TradingView
Alzheimer’s Drug Targets Astrocytes, Not Amyloid: Pepinemab Advances to Phase 2b - Tech Times
Vaccinex to Present Novel Glial Biomarker Data for Pepinemab at AAIC 2026, Outlining Path to Phase 2b in Alzheimer's Disease - BioPharm International
Vaccinex to present new biomarker data and Phas... - Pluang
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026 - The Manila Times
Vaccinex to Present New Biomarker Data From SIGNAL-AD Study Supporting Expanded Phase 2b Trial of Pepinemab in Early Alzheimer’s Disease - Quiver Quantitative
Vaccinex to show new Alzheimer’s biomarker data in London - Stock Titan
Vaccinex to Report New Biomarker Data and Plans for Phase - GlobeNewswire
If You Invested $1,000 in Vaccinex Inc (VCNX) - Stock Titan
ADTX Stock Price and Chart — OTC:ADTX - tradingview.com
Price to book forward of Vaccinex, Inc. – OTC:VCNX - TradingView
Price to earnings forward of Vaccinex, Inc. – OTC:VCNX - TradingView
Vaccinex, Inc. Actuals & Estimates (OTC:VCNX) - TradingView
Enterprise value to revenue forward of Vaccinex, Inc. – OTC:VCNX - TradingView
Price to sales forward of Vaccinex, Inc. – OTC:VCNX - TradingView
Agitation in Alzheimer's Disease Market to Register Immense Growth at a CAGR of 14.9% During the Forecast Period (2026-2036) | DelveInsight - PR Newswire UK
Vaccinex Inc stock (US91831V1026): Biotech small cap focuses on neurology and oncology after recent - Ad-hoc-news.de
Vaccinex, Inc.Common Stock (NQ: VCNX - The Chronicle-Journal
Vaccinex Inc (VCNX) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Vaccinex Inc (VCNX) Stock Earnings Transcripts - GuruFocus
Vaccinex Inc (VCNX) Stock Price & 30 Year Financial Data - GuruFocus
Vaccinex Inc stock (US91831V1026): Biotech innovator in neuroscience - AD HOC NEWS
Vaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025 | VCNX Stock News - Quiver Quantitative
Vaccinex posts 2025 financial statements for clinical-stage biotech - Stock Titan
Vaccinex Reports 2025 Annual Financial Results - The Manila Times
Vaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025 - Quiver Quantitative
Vaccinex Inc stock (US91831V1026): Is its immunotherapy pipeline strong enough to unlock biotech ups - AD HOC NEWS
LABT Stock Price and Chart — NASDAQ:LABT - TradingView
DCOY Stock Price and Chart — NASDAQ:DCOY - tradingview.com
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease - Yahoo Finance
Health Experts Slam Possible FDA ‘Black Box’ Warning for COVID Vaccines - Scientific American
BNBX Stock Price and Chart — NASDAQ:BNBX - TradingView
NF-κB Inhibitors Market to Witness Accelerated Expansion Across the 7MM through 2034 | DelveInsight - PR Newswire UK
GLP-1 Agonists Market to Show Impressive Growth at a CAGR of 10.8% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire
PPCB Stock Price and Chart — NASDAQ:PPCB - TradingView
Highest-Paid CEOs - AFL-CIO
Alzheimer’s Therapeutics Market on Upward Trajectory Across - GlobeNewswire
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting - Barchart.com
Vaccinex (VCNX) Stock Price, News & Analysis - Stock Titan
NBCO Stock Price, News & Analysis - Stock Titan
ENZOLYTICS (ENZC) Stock Price, News & Analysis - stocktitan.net
OCEA Stock Price, News & Analysis - Stock Titan
ADXS Stock Price, News & Analysis - Stock Titan
Vaccinex Inc (VCNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.05%
0.82%
자본화:
|
볼륨(24시간):